Atherosclerosis: From Pathogenesis to Therapeutic Interventions
MedComm · 2026-11 · 7 (11)
DOI: 10.1002/mco2.71095 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 29.10.2026. Verfasst von Enge Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, The Second Affiliated Hospital, Jiangxi Medical College Nanchang University Nanchang Jiangxi China. Die Arbeit nennt 312 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangxi Province.
Abstract (Originalsprache)
Atherosclerosis is no longer viewed solely as a lipid‐storage disorder but rather as a complex multisystem inflammatory disease driven by interactions among the vascular, immune, metabolic, and nervous systems. This review integrates recent concepts, including trained immunity, the neuroimmune cardiovascular interface, vascular cell plasticity, and the microbiome–vascular axis, that reshape the understanding of plaque initiation, progression, and instability. We summarize how established lipid‐lowering, antidiabetic, antihypertensive, and revascularization strategies influence atherosclerotic disease and discuss emerging interventions, including RNA therapeutics, anti‐inflammatory agents, gene therapy, and cell‐based approaches. Key ongoing clinical trials that may clarify the cardiovascular benefits and safety of these strategies are also reviewed. Despite therapeutic advances, residual cardiovascular risk persists because of limitations in animal models, sex‐related differences in plaque phenotype, and the lack of clinically applicable biomarkers. Nanotechnology, human microphysiological systems, spatial multiomics, and artificial intelligence may help bridge these translational gaps. Successful clinical implementation will nevertheless require biomarker‐guided patient selection, rational combination therapy, validated surrogate endpoints, long‐term safety assessment, and attention to health economics. In summary, these advances will shape future translational research and clinical trial design, ultimately advancing personalized management of atherosclerosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, The Second Affiliated Hospital, Jiangxi Medical College Nanchang University Nanchang Jiangxi China.
- Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Jiangxi Medical College Nanchang University Nanchang Jiangxi China.
- Affiliated Rehabilitation Hospital of Nanchang University Nanchang Jiangxi China.
ORCID-Profile: Nianlong Yan, Long Jiang
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangxi Province
Zitieren
APA
Zhou, E., Zhan, C., Li, Y., Zeng, Y., Luo, R., Ouyang, X., Liu, S., Yang, R., Yan, N., & Jiang, L. (2026). Atherosclerosis: From Pathogenesis to Therapeutic Interventions. MedComm, 7(11). https://doi.org/10.1002/mco2.71095
Vancouver
Zhou E, Zhan C, Li Y, Zeng Y, Luo R, Ouyang X, et al. Atherosclerosis: From Pathogenesis to Therapeutic Interventions. MedComm. 2026;7(11). doi:10.1002/mco2.71095
BibTeX
@article{Zhou2026,
author = {Zhou, Enge and Zhan, Chenxi and Li, Yuting and Zeng, Yi and Luo, Renfei and Ouyang, Xin and Liu, Shixing and Yang, Renqiang and Yan, Nianlong and Jiang, Long},
title = {Atherosclerosis: From Pathogenesis to Therapeutic Interventions},
journal = {MedComm},
year = {2026},
volume = {7},
number = {11},
doi = {10.1002/mco2.71095}
}
EUVIMED